Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 31
Journal of Pharmaceutical Negative Results ; 13:258-263, 2022.
Article in English | EMBASE | ID: covidwho-2273863
International Journal on Disability and Human Development ; 21(3):231-237, 2022.
Article in English | EMBASE | ID: covidwho-2168624
2nd International Conference on Computing and Machine Intelligence, ICMI 2022 ; 2022.
Article in English | Scopus | ID: covidwho-2063264
2nd International Conference on Computing and Machine Intelligence, ICMI 2022 ; 2022.
Article in English | Scopus | ID: covidwho-2063260
Archives of psychiatry research ; 58(1):73-80, 2022.
Article in English | EMBASE | ID: covidwho-1998112
American Journal of Respiratory and Critical Care Medicine ; 205:2, 2022.
Article in English | English Web of Science | ID: covidwho-1880003
Am J Respir Crit Care Med ; 205(11): 1290-1299, 2022 06 01.
Article in English | MEDLINE | ID: covidwho-1874930


Rationale: GM-CSF (granulocyte-macrophage colony-stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19). Objectives: We sought to investigate the efficacy and safety of gimsilumab, an anti-GM-CSF monoclonal antibody, for the treatment of hospitalized patients with elevated inflammatory markers and hypoxemia secondary to COVID-19. Methods: We conducted a 24-week randomized, double-blind, placebo-controlled trial, BREATHE (Better Respiratory Education and Treatment Help Empower), at 21 locations in the United States. Patients were randomized 1:1 to receive two doses of intravenous gimsilumab or placebo 1 week apart. The primary endpoint was all-cause mortality rate at Day 43. Key secondary outcomes were ventilator-free survival rate, ventilator-free days, and time to hospital discharge. Enrollment was halted early for futility based on an interim analysis. Measurements and Main Results: Of the planned 270 patients, 225 were randomized and dosed; 44.9% of patients were Hispanic or Latino. The gimsilumab and placebo groups experienced an all-cause mortality rate at Day 43 of 28.3% and 23.2%, respectively (adjusted difference = 5% vs. placebo; 95% confidence interval [-6 to 17]; P = 0.377). Overall mortality rates at 24 weeks were similar across the treatment arms. The key secondary endpoints demonstrated no significant differences between groups. Despite the high background use of corticosteroids and anticoagulants, adverse events were generally balanced between treatment groups. Conclusions: Gimsilumab did not improve mortality or other key clinical outcomes in patients with COVID-19 pneumonia and evidence of systemic inflammation. The utility of anti-GM-CSF therapy for COVID-19 remains unclear. Clinical trial registered with (NCT04351243).

COVID-19 Drug Treatment , Antibodies, Monoclonal, Humanized/therapeutic use , Double-Blind Method , Humans , Inflammation
IEEE Region 10 Symposium (TENSYMP) - Good Technologies for Creating Future ; 2021.
Article in English | Web of Science | ID: covidwho-1853488
Infektoloski Glasnik ; 41(3):87-92, 2021.
Article in English | EMBASE | ID: covidwho-1822781
Trends Food Sci Technol ; 104: 219-234, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-1791132


BACKGROUND: Garlic (Allium sativum L.) is a common herb consumed worldwide as functional food and traditional remedy for the prevention of infectious diseases since ancient time. Garlic and its active organosulfur compounds (OSCs) have been reported to alleviate a number of viral infections in pre-clinical and clinical investigations. However, so far no systematic review on its antiviral effects and the underlying molecular mechanisms exists. SCOPE AND APPROACH: The aim of this review is to systematically summarize pre-clinical and clinical investigations on antiviral effects of garlic and its OSCs as well as to further analyse recent findings on the mechanisms that underpin these antiviral actions. PubMed, Cochrane library, Google Scholar and Science Direct databases were searched and articles up to June 2020 were included in this review. KEY FINDINGS AND CONCLUSIONS: Pre-clinical data demonstrated that garlic and its OSCs have potential antiviral activity against different human, animal and plant pathogenic viruses through blocking viral entry into host cells, inhibiting viral RNA polymerase, reverse transcriptase, DNA synthesis and immediate-early gene 1(IEG1) transcription, as well as through downregulating the extracellular-signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling pathway. The alleviation of viral infection was also shown to link with immunomodulatory effects of garlic and its OSCs. Clinical studies further demonstrated a prophylactic effect of garlic in the prevention of widespread viral infections in humans through enhancing the immune response. This review highlights that garlic possesses significant antiviral activity and can be used prophylactically in the prevention of viral infections.

Prog Brain Res ; 270(1): xix-xx, 2022.
Article in English | MEDLINE | ID: covidwho-1799652
2021 International Conference on Computing, Electronic and Electrical Engineering, ICE Cube 2021 ; 2021.
Article in English | Scopus | ID: covidwho-1672724
World Journal of Laparoscopic Surgery ; 14(1):65-67, 2021.
Article in English | Scopus | ID: covidwho-1456431